ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
123.507,35
-0,81%
S&P 500
5.572,07
-0,76%
US Dollar vs BRL
5,808
-0,79%
Bitcoin
83.159,74
5,97%
Brent Oil
69,725
0,99%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Design Therapeutics Inc (DSGN)

  7. Design Therapeutics Inc (DSGN) Notícias

DSGN

Design Therapeutics (DSGN)

Design Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DSGN
DataHoraFonteTítuloCódigoCompanhia
10/03/202508:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DSGNDesign Therapeutics Inc
10/03/202508:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DSGNDesign Therapeutics Inc
10/03/202508:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DSGNDesign Therapeutics Inc
10/03/202508:07GlobeNewswire Inc.Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
03/03/202510:00GlobeNewswire Inc.Design Therapeutics to Participate in Leerink’s Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
07/02/202518:16Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
06/01/202521:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DSGNDesign Therapeutics Inc
13/11/202410:00GlobeNewswire Inc.Design Therapeutics to Participate in Multiple Upcoming Investor ConferencesNASDAQ:DSGNDesign Therapeutics Inc
07/11/202418:01GlobeNewswire Inc.Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioNASDAQ:DSGNDesign Therapeutics Inc
10/09/202409:00GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
09/08/202417:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DSGNDesign Therapeutics Inc
05/08/202409:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DSGNDesign Therapeutics Inc
05/08/202409:00GlobeNewswire Inc.Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioNASDAQ:DSGNDesign Therapeutics Inc
08/05/202417:05GlobeNewswire Inc.Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesNASDAQ:DSGNDesign Therapeutics Inc
07/05/202407:30GlobeNewswire Inc.Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
19/03/202417:01GlobeNewswire Inc.Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
19/03/202408:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:DSGNDesign Therapeutics Inc
12/03/202407:30GlobeNewswire Inc.Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateNASDAQ:DSGNDesign Therapeutics Inc
13/11/202318:05GlobeNewswire Inc.Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024NASDAQ:DSGNDesign Therapeutics Inc
06/09/202318:13Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DSGNDesign Therapeutics Inc
14/08/202317:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
14/08/202317:01GlobeNewswire Inc.Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaNASDAQ:DSGNDesign Therapeutics Inc
02/06/202317:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DSGNDesign Therapeutics Inc
01/06/202317:46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DSGNDesign Therapeutics Inc
31/05/202307:30GlobeNewswire Inc.Design Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:DSGNDesign Therapeutics Inc
09/05/202317:05GlobeNewswire Inc.Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsNASDAQ:DSGNDesign Therapeutics Inc
24/04/202307:30GlobeNewswire Inc.Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023NASDAQ:DSGNDesign Therapeutics Inc
13/04/202317:41Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DSGNDesign Therapeutics Inc
03/04/202317:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:DSGNDesign Therapeutics Inc
14/03/202317:27Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:DSGNDesign Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DSGN

Seu Histórico Recente

COIN
WITEUR
Witnet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios